BACE1 and Alzheimer disease: The increase of almost 61% of BACE1 serum activity we achieved, is in line with 53% increase in MCI and 68% in AD showed by Shen and co-authors [11], and of 30% in late onset AD reported by Zuliani et al. (2021) [13].